

Sun Pharmaceutical Industries Ltd.,

FORM D

(as prescribed by SEBI under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992
[Regulation 13(4) and (6)])

Regulation 13(6) — Details of change in shareholding by Director or Officer of a listed Company and his dependents

Company Name : Sun Pharmaceutical Industries Limited

Name, PAN No. & Address of Officer	No. & % of shares/ voting rights held by the Officer	Date of receipt of allotment advice/acq uisition - sale of shares	Date of intimation to company	Mode of sale acquisition (market purchase/ public/ rights/ preferential offer etc.)	No. & % of shares /post acquisition /voting rights sale-	Trading member through whom the trade was executed with SEBI Registrati on No. of the TM	Exchan ge on which the trade was execute d	Buy quantit y	Buy value	Sell quantity
Sadhana K. Ganorkar PAN No. AKKPG5544K Address Flat No. A/402 – Lakshachandi Heights, Krishnavatika Marg, Gokuldham, Goregaon (East) Mumbai 400 063	5095 & % Negligible	01.10.2012	3.10.2012	Market sale	795 & % Negligible	Ventura Securities Ltd. SEBI Regn No. INB01076 0438	BSE	N.A.	N.A.	4,300

For Sun Pharmaceutical Industries Ltd.,

Ashok Bhuta
Compliance Officer

Date: 04.10.2012

October 4, 2012

1. National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
2. Bombay Stock Exchange Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Re: Disclosure under Regulation 13 (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Pursuant to the Regulation 13 (6) of the SEBI (Prohibition of Insider Trading) Regulations 1992, this is to inform you that the Company has received the disclosure in Form D under Regulation 13 (4) of the SEBI (Prohibition of Insider Trading) Regulations 1992 from Mr. Kirti Ganorkar, designated employee of the Company, stating that his dependemt, Ms.Sadhana K. Ganorkar has sold by way of market sale 4300 Equity shares of the Company on 01.10.2012 and that after the aforesaid sale, her shareholding in the Company will be 795 Equity Shares (i.e negligible % of the total paid up Equity Share capital of the Company).

Please find herewith the disclosure in the prescribed Form D under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations 1992, based on the disclosure received from Mr. Kirti Ganorkar, designated employee of the Company under Regulation 13 (4) of the SEBI (Prohibition of Insider Trading) Regulations 1992.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd.,

Ashok Bhuta
Compliance Officer

Encl: As above